8 results
Anti-Selection & Genetic Testing in Insurance: An Interdisciplinary Perspective
- Dexter Golinghorst, Aisling de Paor, Yann Joly, Angus S. Macdonald, Margaret Otlowski, Richard Peter, Anya E.R. Prince
-
- Journal:
- Journal of Law, Medicine & Ethics / Volume 50 / Issue 1 / Spring 2022
- Published online by Cambridge University Press:
- 04 March 2022, pp. 139-154
- Print publication:
- Spring 2022
-
- Article
- Export citation
-
Anti-selection occurs when information asymmetry exists between insurers and applicants. When an applicant knows they are at high risk of loss, but the insurer does not, the applicant may try to use this knowledge differential to secure insurance at a lower premium that does not match risk.
Nuclear magnetic resonance spectroscopy as a tool to study carbohydrate metabolism
- Peter G. Morris, Dominick J. O. McIntyre, Ron Coxon, Herman S. Bachelard, And K. Tim Moriarty, Paul L. Greenhaff, Ian A. MacDonald
-
- Journal:
- Proceedings of the Nutrition Society / Volume 53 / Issue 2 / July 1994
- Published online by Cambridge University Press:
- 03 August 2018, pp. 335-343
-
- Article
-
- You have access Access
- Export citation
Clopyralid Tolerance in Strawberry and Feasibility of Early Applications in Florida
- Shaun M. Sharpe, Nathan S. Boyd, Peter J. Dittmar, Greg E. MacDonald, Rebecca L. Darnell
-
- Journal:
- Weed Science / Volume 66 / Issue 4 / July 2018
- Published online by Cambridge University Press:
- 10 April 2018, pp. 508-515
-
- Article
-
- You have access Access
- HTML
- Export citation
-
Broadleaf species escape current integrated weed management strategies in strawberry [Fragaria×ananassa (Weston) Duchesne ex Rozier (pro sp.) [chiloensis×virginiana]] production. Clopyralid is a registered POST control option, but current application timings provide suppression of only some species. Earlier clopyralid application timings may increase spray coverage to weeds at the planting hole, but strawberry plant tolerance to applications shortly after transplant is unknown. The objectives of the study were to determine the degree of clopyralid tolerance when applied to mature strawberry plants according to current management strategies, whether clopyralid absorption and translocation were involved in the tolerance response demonstrated by mature strawberry plants, and whether clopyralid could be safely applied to immature strawberry plants shortly after transplant. Clopyralid caused no damage when applied to mature strawberry plants and did not affect crop height, number of crowns, flowers, immature berries, or yield. Maximal strawberry absorption of radiolabeled clopyralid was 82% of the recovered radioactivity and reached peak (90%) absorption at 15 h. Maximal total translocation of radioactivity from the treated leaf was 17% and reached peak translocation at 52 h. Translocation was primarily to the new leaves and reproductive structures. In the early-application experiment, damage induced by clopyralid for all application timings reached 0 by 8 wk after treatment. Across all timings, maximal damage at 140 g ha−1 was 17% when applied 14 d after transplant (DATr) and 56% at 28 g ha−1 when applied at 21 DATr. Clopyralid dose did not affect the number of crowns, aboveground biomass, or yield. There was some stunting in plant height (3%) by the high labeled dose of clopyralid. Labeled dose clopyralid applications appear safe for application timings closer to strawberry transplant, though considerations of leaf cupping should be taken under consideration for label changes.
Effect of Temperature on Clopyralid Safety in Strawberry
- Shaun M. Sharpe, Nathan S. Boyd, Peter J. Dittmar, Greg E. MacDonald, Rebecca L. Darnell
-
- Journal:
- Weed Technology / Volume 32 / Issue 3 / June 2018
- Published online by Cambridge University Press:
- 02 February 2018, pp. 347-351
-
- Article
- Export citation
-
Strawberry is an important horticultural crop in Florida. The long growing season and escapes from fumigation and PRE herbicides necessitate POST weed management to maximize harvest potential and efficiency. Alternatives to hand-weeding are desirable, but clopyralid is the only broadleaf herbicide registered for use. Weed control may be improved by early-season clopyralid applications, but at risk of high temperature and increased strawberry injury. The effect of temperature on clopyralid safety on strawberry is unknown. We undertook a growth chamber experiment using a completely randomized design to determine crop safety under various temperature conditions across acclimation, herbicide application, and post-application periods. There was no effect of clopyralid on the number of strawberry leaves across all temperatures. Damage to the strawberry manifested as leaf malformations. Acclimation temperatures affected clopyralid-associated injury (p=0.0309), with increased leaf malformations at higher temperatures (27 C) compared to lower (18 C) temperatures. Pre-treatment temperatures did not affect clopyralid injury. Post-application temperature also affected clopyralid injury (p=0.0161), with increased leaf malformations at higher temperatures compared to lower ones. Clopyralid application did not reduce flowering or biomass production in the growth chamber. If leaf malformations are to be avoided, consideration to growing conditions prior to application is advisable, especially if applying clopyralid early in the season.
Spray Penetration into a Strawberry Canopy as Affected by Canopy Structure, Nozzle Type, and Application Volume
- Shaun M. Sharpe, Nathan S. Boyd, Peter J. Dittmar, Greg E. MacDonald, Rebecca L. Darnell, Jason A. Ferrell
-
- Journal:
- Weed Technology / Volume 32 / Issue 1 / February 2018
- Published online by Cambridge University Press:
- 17 November 2017, pp. 80-84
-
- Article
-
- You have access Access
- HTML
- Export citation
-
Strawberries, an important Florida crop, are grown on raised beds covered with plastic mulch. The plastic mulch provides good control of many weeds, but some problem species can emerge from the transplant hole during crop establishment. POST herbicide options for broadleaf weed control within the strawberry bed is limited to clopyralid, which only provides suppression. Strawberry canopy shielding may be responsible for the observed incomplete control with clopyralid application for problematic broadleaf weed species such as black medic and Carolina geranium. Two field experiments were established on mature strawberries to evaluate spray penetration through the canopy. The first examined spray penetration through the canopy of multiple strawberry cultivars at various distances from the crown. The second examined the effects of application volumes and nozzle selection on spray penetration. Cultivar selection had no effect on spray penetration through the canopy. In the first study, when applying at 281 L ha−1, the area around the planting hole (0 to 5 cm from the crown) had 8% coverage below the canopy while the area below the canopy edge (10 to 15 cm from the crown) had 27% coverage. In the second study, increasing the application volume from 187 to 375 L ha−1 increased coverage by 81%. Increasing the application volume from 375 to 740 L ha−1 increased coverage 33% with maximal coverage of 53% at 740 L ha−1. Nozzle type (standard even flat spray tip, Drift Guard, or TwinJet nozzles) did not affect coverage or deposition volume below the canopy. Overall, mature strawberry canopies demonstrated similar spray droplet penetration across cultivars with increased penetration with increased distance from the crown. Penetration increased with increasing application volume, but the nozzle types used in this experiment did not affect penetration. Additional research is needed to better define the effect of application volume on herbicide efficacy.
Control Recommendations for Black Medic (Medicago lupulina) Based on Growth and Development in Competition with Strawberry
- Shaun M. Sharpe, Nathan S. Boyd, Peter J. Dittmar, Greg E. MacDonald, Rebecca L. Darnell, Jason A. Ferrell
-
- Journal:
- Weed Science / Volume 66 / Issue 2 / March 2018
- Published online by Cambridge University Press:
- 06 October 2017, pp. 226-233
-
- Article
-
- You have access Access
- HTML
- Export citation
-
Strawberries are an important horticultural crop in Florida. Black medic is among the most problematic weeds within the production system. To better coordinate control measures, black medic growth and development while in competition with strawberry was studied. Twelve plants were randomly selected at each of four field sites in Hillsborough County, FL, in 2014. Plants were repeatedly measured over the growing season for stem length and number of primary branches, flower buds, flowers, and seed clusters. Growing degree days (GDD) were calculated (Tbase=0 C) starting from the hole-punch application of the plastic mulch (October 8, 2014, to October 10, 2014) from weather station data generated from the Florida Automated Weather Network. Strawberry height and width increased consistently across all sites, but black medic growth and development varied considerably. Strawberry suppressed black medic growth up to 1,805 cumulative GDD at three of four sites where black medic remained beneath the strawberry canopy. After 1,805 GDD, the black medic stems still remained below but experienced exponential growth for total stem length and, in turn, flower buds, inflorescence, and immature seed clusters. Ideal clopyralid spray timing based on susceptible plant size was 890 to 1,152 GDD. Optimal hand-weeding time frames would likely occur as the plant stems expand beyond the strawberry canopy (to improve visibility) and before flower production to prevent seed return to the seedbank. First seed production was observed at 1,200 GDD at the earliest site and between 1,966 to 2,365 GDD across all the other sites. Overall, consistent trends were observed across sites, but between-site variability was observed that could not be accounted for by differences in temperature.
Contributors
-
- By Mitchell Aboulafia, Frederick Adams, Marilyn McCord Adams, Robert M. Adams, Laird Addis, James W. Allard, David Allison, William P. Alston, Karl Ameriks, C. Anthony Anderson, David Leech Anderson, Lanier Anderson, Roger Ariew, David Armstrong, Denis G. Arnold, E. J. Ashworth, Margaret Atherton, Robin Attfield, Bruce Aune, Edward Wilson Averill, Jody Azzouni, Kent Bach, Andrew Bailey, Lynne Rudder Baker, Thomas R. Baldwin, Jon Barwise, George Bealer, William Bechtel, Lawrence C. Becker, Mark A. Bedau, Ernst Behler, José A. Benardete, Ermanno Bencivenga, Jan Berg, Michael Bergmann, Robert L. Bernasconi, Sven Bernecker, Bernard Berofsky, Rod Bertolet, Charles J. Beyer, Christian Beyer, Joseph Bien, Joseph Bien, Peg Birmingham, Ivan Boh, James Bohman, Daniel Bonevac, Laurence BonJour, William J. Bouwsma, Raymond D. Bradley, Myles Brand, Richard B. Brandt, Michael E. Bratman, Stephen E. Braude, Daniel Breazeale, Angela Breitenbach, Jason Bridges, David O. Brink, Gordon G. Brittan, Justin Broackes, Dan W. Brock, Aaron Bronfman, Jeffrey E. Brower, Bartosz Brozek, Anthony Brueckner, Jeffrey Bub, Lara Buchak, Otavio Bueno, Ann E. Bumpus, Robert W. Burch, John Burgess, Arthur W. Burks, Panayot Butchvarov, Robert E. Butts, Marina Bykova, Patrick Byrne, David Carr, Noël Carroll, Edward S. Casey, Victor Caston, Victor Caston, Albert Casullo, Robert L. Causey, Alan K. L. Chan, Ruth Chang, Deen K. Chatterjee, Andrew Chignell, Roderick M. Chisholm, Kelly J. Clark, E. J. Coffman, Robin Collins, Brian P. Copenhaver, John Corcoran, John Cottingham, Roger Crisp, Frederick J. Crosson, Antonio S. Cua, Phillip D. Cummins, Martin Curd, Adam Cureton, Andrew Cutrofello, Stephen Darwall, Paul Sheldon Davies, Wayne A. Davis, Timothy Joseph Day, Claudio de Almeida, Mario De Caro, Mario De Caro, John Deigh, C. F. Delaney, Daniel C. Dennett, Michael R. DePaul, Michael Detlefsen, Daniel Trent Devereux, Philip E. Devine, John M. Dillon, Martin C. Dillon, Robert DiSalle, Mary Domski, Alan Donagan, Paul Draper, Fred Dretske, Mircea Dumitru, Wilhelm Dupré, Gerald Dworkin, John Earman, Ellery Eells, Catherine Z. Elgin, Berent Enç, Ronald P. Endicott, Edward Erwin, John Etchemendy, C. Stephen Evans, Susan L. Feagin, Solomon Feferman, Richard Feldman, Arthur Fine, Maurice A. Finocchiaro, William FitzPatrick, Richard E. Flathman, Gvozden Flego, Richard Foley, Graeme Forbes, Rainer Forst, Malcolm R. Forster, Daniel Fouke, Patrick Francken, Samuel Freeman, Elizabeth Fricker, Miranda Fricker, Michael Friedman, Michael Fuerstein, Richard A. Fumerton, Alan Gabbey, Pieranna Garavaso, Daniel Garber, Jorge L. A. Garcia, Robert K. Garcia, Don Garrett, Philip Gasper, Gerald Gaus, Berys Gaut, Bernard Gert, Roger F. Gibson, Cody Gilmore, Carl Ginet, Alan H. Goldman, Alvin I. Goldman, Alfonso Gömez-Lobo, Lenn E. Goodman, Robert M. Gordon, Stefan Gosepath, Jorge J. E. Gracia, Daniel W. Graham, George A. Graham, Peter J. Graham, Richard E. Grandy, I. Grattan-Guinness, John Greco, Philip T. Grier, Nicholas Griffin, Nicholas Griffin, David A. Griffiths, Paul J. Griffiths, Stephen R. Grimm, Charles L. Griswold, Charles B. Guignon, Pete A. Y. Gunter, Dimitri Gutas, Gary Gutting, Paul Guyer, Kwame Gyekye, Oscar A. Haac, Raul Hakli, Raul Hakli, Michael Hallett, Edward C. Halper, Jean Hampton, R. James Hankinson, K. R. Hanley, Russell Hardin, Robert M. Harnish, William Harper, David Harrah, Kevin Hart, Ali Hasan, William Hasker, John Haugeland, Roger Hausheer, William Heald, Peter Heath, Richard Heck, John F. Heil, Vincent F. Hendricks, Stephen Hetherington, Francis Heylighen, Kathleen Marie Higgins, Risto Hilpinen, Harold T. Hodes, Joshua Hoffman, Alan Holland, Robert L. Holmes, Richard Holton, Brad W. Hooker, Terence E. Horgan, Tamara Horowitz, Paul Horwich, Vittorio Hösle, Paul Hoβfeld, Daniel Howard-Snyder, Frances Howard-Snyder, Anne Hudson, Deal W. Hudson, Carl A. Huffman, David L. Hull, Patricia Huntington, Thomas Hurka, Paul Hurley, Rosalind Hursthouse, Guillermo Hurtado, Ronald E. Hustwit, Sarah Hutton, Jonathan Jenkins Ichikawa, Harry A. Ide, David Ingram, Philip J. Ivanhoe, Alfred L. Ivry, Frank Jackson, Dale Jacquette, Joseph Jedwab, Richard Jeffrey, David Alan Johnson, Edward Johnson, Mark D. Jordan, Richard Joyce, Hwa Yol Jung, Robert Hillary Kane, Tomis Kapitan, Jacquelyn Ann K. Kegley, James A. Keller, Ralph Kennedy, Sergei Khoruzhii, Jaegwon Kim, Yersu Kim, Nathan L. King, Patricia Kitcher, Peter D. Klein, E. D. Klemke, Virginia Klenk, George L. Kline, Christian Klotz, Simo Knuuttila, Joseph J. Kockelmans, Konstantin Kolenda, Sebastian Tomasz Kołodziejczyk, Isaac Kramnick, Richard Kraut, Fred Kroon, Manfred Kuehn, Steven T. Kuhn, Henry E. Kyburg, John Lachs, Jennifer Lackey, Stephen E. Lahey, Andrea Lavazza, Thomas H. Leahey, Joo Heung Lee, Keith Lehrer, Dorothy Leland, Noah M. Lemos, Ernest LePore, Sarah-Jane Leslie, Isaac Levi, Andrew Levine, Alan E. Lewis, Daniel E. Little, Shu-hsien Liu, Shu-hsien Liu, Alan K. L. Chan, Brian Loar, Lawrence B. Lombard, John Longeway, Dominic McIver Lopes, Michael J. Loux, E. J. Lowe, Steven Luper, Eugene C. Luschei, William G. Lycan, David Lyons, David Macarthur, Danielle Macbeth, Scott MacDonald, Jacob L. Mackey, Louis H. Mackey, Penelope Mackie, Edward H. Madden, Penelope Maddy, G. B. Madison, Bernd Magnus, Pekka Mäkelä, Rudolf A. Makkreel, David Manley, William E. Mann (W.E.M.), Vladimir Marchenkov, Peter Markie, Jean-Pierre Marquis, Ausonio Marras, Mike W. Martin, A. P. Martinich, William L. McBride, David McCabe, Storrs McCall, Hugh J. McCann, Robert N. McCauley, John J. McDermott, Sarah McGrath, Ralph McInerny, Daniel J. McKaughan, Thomas McKay, Michael McKinsey, Brian P. McLaughlin, Ernan McMullin, Anthonie Meijers, Jack W. Meiland, William Jason Melanson, Alfred R. Mele, Joseph R. Mendola, Christopher Menzel, Michael J. Meyer, Christian B. Miller, David W. Miller, Peter Millican, Robert N. Minor, Phillip Mitsis, James A. Montmarquet, Michael S. Moore, Tim Moore, Benjamin Morison, Donald R. Morrison, Stephen J. Morse, Paul K. Moser, Alexander P. D. Mourelatos, Ian Mueller, James Bernard Murphy, Mark C. Murphy, Steven Nadler, Jan Narveson, Alan Nelson, Jerome Neu, Samuel Newlands, Kai Nielsen, Ilkka Niiniluoto, Carlos G. Noreña, Calvin G. Normore, David Fate Norton, Nikolaj Nottelmann, Donald Nute, David S. Oderberg, Steve Odin, Michael O’Rourke, Willard G. Oxtoby, Heinz Paetzold, George S. Pappas, Anthony J. Parel, Lydia Patton, R. P. Peerenboom, Francis Jeffry Pelletier, Adriaan T. Peperzak, Derk Pereboom, Jaroslav Peregrin, Glen Pettigrove, Philip Pettit, Edmund L. Pincoffs, Andrew Pinsent, Robert B. Pippin, Alvin Plantinga, Louis P. Pojman, Richard H. Popkin, John F. Post, Carl J. Posy, William J. Prior, Richard Purtill, Michael Quante, Philip L. Quinn, Philip L. Quinn, Elizabeth S. Radcliffe, Diana Raffman, Gerard Raulet, Stephen L. Read, Andrews Reath, Andrew Reisner, Nicholas Rescher, Henry S. Richardson, Robert C. Richardson, Thomas Ricketts, Wayne D. Riggs, Mark Roberts, Robert C. Roberts, Luke Robinson, Alexander Rosenberg, Gary Rosenkranz, Bernice Glatzer Rosenthal, Adina L. Roskies, William L. Rowe, T. M. Rudavsky, Michael Ruse, Bruce Russell, Lilly-Marlene Russow, Dan Ryder, R. M. Sainsbury, Joseph Salerno, Nathan Salmon, Wesley C. Salmon, Constantine Sandis, David H. Sanford, Marco Santambrogio, David Sapire, Ruth A. Saunders, Geoffrey Sayre-McCord, Charles Sayward, James P. Scanlan, Richard Schacht, Tamar Schapiro, Frederick F. Schmitt, Jerome B. Schneewind, Calvin O. Schrag, Alan D. Schrift, George F. Schumm, Jean-Loup Seban, David N. Sedley, Kenneth Seeskin, Krister Segerberg, Charlene Haddock Seigfried, Dennis M. Senchuk, James F. Sennett, William Lad Sessions, Stewart Shapiro, Tommie Shelby, Donald W. Sherburne, Christopher Shields, Roger A. Shiner, Sydney Shoemaker, Robert K. Shope, Kwong-loi Shun, Wilfried Sieg, A. John Simmons, Robert L. Simon, Marcus G. Singer, Georgette Sinkler, Walter Sinnott-Armstrong, Matti T. Sintonen, Lawrence Sklar, Brian Skyrms, Robert C. Sleigh, Michael Anthony Slote, Hans Sluga, Barry Smith, Michael Smith, Robin Smith, Robert Sokolowski, Robert C. Solomon, Marta Soniewicka, Philip Soper, Ernest Sosa, Nicholas Southwood, Paul Vincent Spade, T. L. S. Sprigge, Eric O. Springsted, George J. Stack, Rebecca Stangl, Jason Stanley, Florian Steinberger, Sören Stenlund, Christopher Stephens, James P. Sterba, Josef Stern, Matthias Steup, M. A. Stewart, Leopold Stubenberg, Edith Dudley Sulla, Frederick Suppe, Jere Paul Surber, David George Sussman, Sigrún Svavarsdóttir, Zeno G. Swijtink, Richard Swinburne, Charles C. Taliaferro, Robert B. Talisse, John Tasioulas, Paul Teller, Larry S. Temkin, Mark Textor, H. S. Thayer, Peter Thielke, Alan Thomas, Amie L. Thomasson, Katherine Thomson-Jones, Joshua C. Thurow, Vzalerie Tiberius, Terrence N. Tice, Paul Tidman, Mark C. Timmons, William Tolhurst, James E. Tomberlin, Rosemarie Tong, Lawrence Torcello, Kelly Trogdon, J. D. Trout, Robert E. Tully, Raimo Tuomela, John Turri, Martin M. Tweedale, Thomas Uebel, Jennifer Uleman, James Van Cleve, Harry van der Linden, Peter van Inwagen, Bryan W. Van Norden, René van Woudenberg, Donald Phillip Verene, Samantha Vice, Thomas Vinci, Donald Wayne Viney, Barbara Von Eckardt, Peter B. M. Vranas, Steven J. Wagner, William J. Wainwright, Paul E. Walker, Robert E. Wall, Craig Walton, Douglas Walton, Eric Watkins, Richard A. Watson, Michael V. Wedin, Rudolph H. Weingartner, Paul Weirich, Paul J. Weithman, Carl Wellman, Howard Wettstein, Samuel C. Wheeler, Stephen A. White, Jennifer Whiting, Edward R. Wierenga, Michael Williams, Fred Wilson, W. Kent Wilson, Kenneth P. Winkler, John F. Wippel, Jan Woleński, Allan B. Wolter, Nicholas P. Wolterstorff, Rega Wood, W. Jay Wood, Paul Woodruff, Alison Wylie, Gideon Yaffe, Takashi Yagisawa, Yutaka Yamamoto, Keith E. Yandell, Xiaomei Yang, Dean Zimmerman, Günter Zoller, Catherine Zuckert, Michael Zuckert, Jack A. Zupko (J.A.Z.)
- Edited by Robert Audi, University of Notre Dame, Indiana
-
- Book:
- The Cambridge Dictionary of Philosophy
- Published online:
- 05 August 2015
- Print publication:
- 27 April 2015, pp ix-xxx
-
- Chapter
- Export citation
Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease
- Eugene Kotlyar, Raymond Sy, Anne M. Keogh, Fiona Kermeen, Peter S. Macdonald, Christopher S. Hayward, Keith D. McNeil, David S. Celermajer
-
- Journal:
- Cardiology in the Young / Volume 16 / Issue 3 / June 2006
- Published online by Cambridge University Press:
- 26 May 2006, pp. 268-274
-
- Article
- Export citation
-
Aims: Bosentan is efficacious in idiopathic pulmonary arterial hypertension, and the variants associated with connective tissue disease, but not currently approved for treatment of pulmonary arterial hypertension due to Eisenmenger's syndrome. We sought to evaluate its effect in adults with Eisenmenger's syndrome. Methods: We administered bosentan on the basis of compassionate use in 23 patients with Eisenmenger's syndrome, aged 37 plus or minus 14 years. Of the patients, 17 had never received specific treatment for pulmonary arterial hypertension, five were transitioned from treprostinil, and one from beraprost to bosentan. We measured functional class, saturation of oxygen, haemoglobin levels and six-minute walk distance at baseline, one, six months and at most recent follow-up. Results: Baseline functional class was IV in three, III in fifteen, and II in five patients. At follow-up, with a mean of 15 plus or minus 10 months, 13 of the 23 patients (57%) had improved by at least one functional class, from a median baseline of III to II (p equal to 0.016), mean saturation of oxygen at rest had increased from 81% to 84% (p equal to 0.001), and levels of haemoglobin had decreased from 178 plus or minus 26 grams per litre to 167 plus or minus 19 grams per litre (p equal to 0.001). Overall, the six-minute walk distance did not change from baseline of 335 metres. The distance walked by those not previously receiving specific therapy, however, improved from 318 plus or minus 129 to 345 plus or minus 123 metres (p equal to 0.03). Conclusion: Treatment of adults with Eisenmenger's syndrome using bosentan significantly improved functional class, saturation of oxygen at rest, and decreased levels of haemoglobin. Treatment with bosentan was associated with improvement in six-minute walk distance in those not previously receiving specific therapy. In patients already in receipt of specific therapy, transition to bosentan resulted in no clinical deterioration.